

# BIO-DIMAX®

## ADVANCED DIINDOLYLMETHANE (DIM) DIETARY SUPPLEMENT BORNE FROM PHARMA DELIVERY TECHNOLOGY

---

### A Scientific Review of Mechanistic Rationale, Bioavailability Challenges, and Delivery Innovations Translating to Nutraceutical Use

#### ABSTRACT

This white paper examines the scientific evolution of diindolylmethane (DIM), long established in clinical and consumer wellness use, into a highly bioavailable nutraceutical enabled by advances in pharmaceutical delivery science. DIM, a bioactive compound formed from indole-3-carbinol in cruciferous vegetables, influences estrogen and androgen metabolism, modulates inflammatory signaling pathways, and supports multiple cellular processes associated with homeostatic balance. Despite this broad mechanistic potential, conventional crystalline DIM demonstrates extremely low aqueous solubility, leading to challenges in bioavailability, tolerability, and consistency of real-world use.

Significant progress emerged through pharmaceutical development programs involving Infemin®, Cezarox®, and Cervikon®, which investigated solubilized DIM formulations for targeted clinical applications. These programs demonstrated that fully soluble forms of DIM can achieve predictable systemic exposure at substantially lower doses than conventional crystalline material. BIO-DiMaX® represents the translation of these pharmaceutical delivery principles to a fit-for-purpose dietary supplement designed to address bioavailability limitations while supporting general male and female endocrine, cellular, and immune health.

This review summarizes DIM's biological mechanisms, historical development, solubility limitations, and the emergence of solubilized DIM technology as a pathway to more consistent, lower-dose nutraceutical applications.

---

#### TABLE OF CONTENTS

1. Background: DIM in Clinical and Consumer Context	5. Pharmacokinetic Advantages of Solubilized DIM
2. Biological Mechanisms of DIM <ul style="list-style-type: none"><li>o 2.1 Estrogen Metabolism Modulation</li><li>o 2.2 Androgen-Related Pathways</li><li>o 2.3 Inflammatory &amp; Immune Signaling</li><li>a. 2.4 Cellular Homeostasis &amp; Detoxification Pathways</li></ul>	6. Translation to Nutraceutical Use: BIO-DiMaX®
3. Limitations of Conventional Crystalline DIM	7. Supporting Scientific & Historical Evidence
4. Turning Point in DIM Formulation <ul style="list-style-type: none"><li>o 4.1 Infemin®</li><li>o 4.2 Cezarox®</li><li>o 4.3 Cervikon®</li></ul>	8. Conclusion
	9. References
	10. Addendums <ul style="list-style-type: none"><li>o Addendum A – DIM Mechanisms Overview</li><li>o Addendum B – Bioavailability Comparison Chart</li></ul>

---

1 These statements have not been evaluated by the Food and Drug Administration. BIO-DiMaX® is a dietary supplement ingredient and is not intended to diagnose, treat, cure, or prevent any disease. The information presented is for scientific and educational purposes only.

---

## 1. BACKGROUND: DIM IN CLINICAL AND CONSUMER CONTEXT

DIM has been widely used in consumer wellness settings to support hormonal balance, cellular health, and detoxification-related pathways. Mechanistic studies have explored its influence on estrogen metabolism, androgen signaling, immune modulation, and cellular responses to oxidative and inflammatory stress.

However, despite its promise, conventional DIM supplements often exhibit:

- Variable absorption
- Dose-dependent tolerability issues
- Unpredictable outcomes

This is due primarily to the compound's inherently poor solubility and hydrophobic crystalline structure. These longstanding challenges motivated the search for improved delivery technologies capable of providing more consistent physiological exposure.

## 2. BIOLOGICAL MECHANISMS OF DIM

### 2.1

#### **Estrogen Metabolism Modulation**

DIM supports the formation of hydroxylated estrogen metabolites and is associated with the balancing of estrogenic pathways. This mechanistic rationale underlies much of its use in general endocrine and cellular wellness.

### 2.2

#### **Androgen-Related Pathways**

DIM interacts with androgen-associated signaling pathways and supports healthy estrogen-to-androgen ratios, contributing to interest in male and female hormonal support applications.

### 2.3

#### **Inflammatory & Immune Signaling**

Studies have demonstrated DIM's effects on NF- $\kappa$ B and other cytokine-related pathways, suggesting a role in maintaining normal inflammatory and immune responses.


### 2.4

#### **Cellular Homeostasis & Detoxification Pathways**

DIM influences cellular processes involving xenobiotic metabolism, oxidative balance, and detoxification-related enzyme systems, contributing to its broad biological relevance.

#### **(See Addendum A – DIM Mechanisms Overview)**

These statements have not been evaluated by the Food and Drug Administration. BIO-DiMaX® is a dietary supplement ingredient and is not intended to diagnose, treat, cure, or prevent any disease. The information presented is for scientific and educational purposes only.



---

### 3. LIMITATIONS OF CONVENTIONAL CRYSTALLINE DIM

Despite extensive investigation, conventional DIM faces well-documented challenges:

- Extremely poor aqueous solubility
- Low and variable bioavailability
- Requirement for high doses to achieve measurable exposure
- Gastrointestinal tolerability limitations at higher doses
- Inconsistent real-world outcomes among consumers

These limitations have driven interest in delivery technologies that improve DIM's solubility and systemic availability.


#### SOLUBILITY OF BIO-DIMAX® VS. CRYSTALLINE DIM

##### Procedure:

- 5 grams of each form in 300 ml distilled water
- Agitated under exact conditions for 5 minutes
- Elapsed time: 20 minutes

##### Conclusion:

- Bio-DiMaX® remains fully soluble in water
- Crystalline DIM is poorly dispersed and insoluble in water with clumping on top and precipitation at the bottom simulating >90% insolubility as found in human GI tract



Bio-DiMaX® exhibiting exceptional solubility in water.



Conventional Crystalline DIM.

---

## 4. A TURNING POINT IN DIM FORMULATION:

The turning point in DIM formulation science came through pharmaceutical research in Eastern Europe, where three distinct DIM-based programs were developed for targeted clinical contexts. These programs collectively demonstrated that the formulation — not merely the molecule — is critical for achieving consistent bioavailability.

***References to pharmaceutical development programs and clinical investigations are provided solely for historical and scientific context. BIO-DiMaX® is not intended for use in the diagnosis, treatment, mitigation, or prevention of any disease.***

### 4.1

#### Infemin®

Infemin® utilized solubilized DIM to achieve consistent systemic levels using significantly lower doses than those required for crystalline DIM. Research emphasized safety, tolerability, and formulation-driven exposure improvements.

### 4.2

#### Cezarox®

Cezarox® explored soluble DIM delivery in respiratory wellness and inflammatory-related contexts. Studies focused on the ability to achieve rapid and predictable absorption at comparatively low doses.

These statements have not been evaluated by the Food and Drug Administration. BIO-DiMaX® is a dietary supplement ingredient and is not intended to diagnose, treat, cure, or prevent any disease. The information presented is for scientific and educational purposes only.

### 4.3

#### Cervikon®

Cervikon® applied advanced powder-based technology to women's cellular health, emphasizing tolerability, patient compliance, and formulation-driven improvements in exposure.

Collectively, these pharmaceutical programs validated a critical insight:

Fully solubilized and enhanced bioavailable forms of DIM achieve consistent systemic exposure at lower doses than crystalline DIM, with improved tolerability and user compliance.

This scientific foundation directly informed the development of nutraceutical-appropriate DIM delivery platforms.



---

## 5. PHARMACOKINETIC ADVANTAGES OF SOLUBILIZED DIM:

A comprehensive meta-analysis of preclinical and human pharmacokinetic data shows that solubilized DIM formulations consistently outperform crystalline and microencapsulated forms.

Within this analysis, BIO-DiMaX®—representing the liquid, fully solubilized DIM lineage derived from the Cezarox®, Infemin®, and Cervikon® programs—In comparative pharmacokinetic evaluations, solubilized DIM formulations within the BIO-DiMaX® lineage were associated with higher measured systemic exposure relative to crystalline DIM. In preclinical models, liquid BIO-DiMaX® demonstrated markedly higher maximum plasma concentrations (C<sub>max</sub>) and AUC values compared to crystalline DIM administered at equivalent mg/kg doses representing up to 35X greater bioavailability.

Notably, certain studies identified supra-proportional increases in exposure with increasing doses of solubilized DIM, suggesting partial saturation of elimination pathways and a nonlinear pharmacokinetic profile. This phenomenon was not observed with crystalline DIM and underscores the importance of formulation-enabled dispersion prior to absorption.

These pharmacokinetic findings demonstrate that BIO-DiMaX® delivers more consistent and predictable absorption characteristics at lower functional use levels compared to conventional crystalline DIM. By prioritizing advanced solubilization and dispersion technologies, BIO-DiMaX® is designed to address known formulation challenges associated with DIM, supporting improved consistency and tolerability for use in dietary supplement applications.


**(See Addendum B - Bioavailability Comparison Chart)**

### PHARMACOKINETICS AND BIOAVAILABILITY

Bio-DiMaX® boasts a significantly enhanced bioavailability compared to traditional crystalline DIM. Bio-DiMaX® demonstrates up to ~35-fold greater absorption efficiency in comparative studies.

This remarkable difference translates to a more potent and effective impact on target tissues, optimizing its potential benefits.

By enhancing solubility and dispersion prior to absorption, BIO-DiMaX® is designed to support more consistent systemic availability relative to conventional crystalline DIM



---

## 6. TRANSLATION TO NUTRACEUTICAL USE: BIO-DIMAX®

BIO-DiMaX® represents the adaptation of pharmaceutical-grade DIM solubilization principles into a dietary supplement format intended for general wellness. Developed through a licensing partnership involving intellectual property from the Cezarox®, Infemin®, and Cervikon® programs, BIO-DiMaX® applies advanced delivery technologies to address the practical challenges associated with DIM supplementation.

### **BIO-DiMaX® is designed to support:**

- Improved solubility and dispersion
- Lower functional dosing (e.g., 25–50 mg daily suggested use)
- Improve tolerability
- A more consistent user experience

These characteristics reflect the same formulation concepts that allowed pharmaceutical versions of DIM to achieve predictable exposure at lower doses relative to crystalline DIM.



## 7. SUPPORTING SCIENTIFIC & HISTORICAL EVIDENCE

The white paper's evidence base includes:

- Mechanistic studies on DIM
- Pharmacokinetic insights from solubilized DIM formulations
- Historical development timelines from Infemin®, Cezarox®, and Cervikon®
- Published safety and tolerability findings
- Patent documents supporting solubilized DIM technologies

This evidence illustrates the evolution of DIM from a mechanistically interesting compound to a more technologically sophisticated form enabled by delivery science.

***BIO-DiMaX® is a dietary supplement ingredient developed for use in general wellness applications. All references to biological mechanisms, pharmacokinetic observations, and historical pharmaceutical research are provided for scientific context and do not constitute medical claims.***

## 8. CONCLUSION

DIM has a long history of scientific and consumer interest, but its practical application has been limited by low solubility, variable absorption, and tolerability challenges. Research in advanced formulation science has shown that delivery design significantly influences DIM's absorption characteristics.

BIO-DiMaX® represents the application of these formulation-driven insights in a nutraceutical format, designed to support consistent performance, tolerability, and ease of use in dietary supplement formulations.

## REFERENCES

- Higdon, J. V., Delage, B., Williams, D. E., & Dashwood, R. H. (2007). Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. *Pharmacol Res*, 55(3), 224–236.
- Reed, G. A., et al. (2006). A phase I study of indole-3-carbinol in women: tolerability and effects on 2- and 16 $\alpha$ -hydroxyestrone metabolism. *Cancer Epidemiol Biomarkers Prev*, 15(12), 2477–2481.
- Takada, Y., Andreeff, M., & Aggarwal, B. B. (2005). Indole-3-carbinol suppresses NF- $\kappa$ B and potentiates TNF-induced apoptosis. *J Biol Chem*, 280(6), 5128–5138.
- Kim, E. J., Park, S. Y., & Kim, Y. (2019). 3,3'-Diindolylmethane suppresses inflammatory responses via inhibition of NF- $\kappa$ B and activation of Nrf2 in macrophages. *Int Immunopharmacol*, 68, 158–167.
- Firestone, G. L., & Bjeldanes, L. F. (2003). Indole-3-carbinol and 3,3'-diindolylmethane anti-cancer mechanisms of action. *Biofactors*, 18(1–4), 255–261.
- Zeligs, M. A. (2011). The effect of diindolylmethane on prostate health: Clinical observations and mechanisms of action. *Integrative Cancer Therapies*, 10(3), 240–249.
- Anderton, M. J., Manson, M. M., Verschoyle, R. D., Gescher, A., Steward, W. P., Williams, M. L., & Mager, D. E. (2004). Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. *Clinical Cancer Research*, 10(15), 5233–5241.
- Bjeldanes, L. F., Kim, J. Y., Grose, K. R., Bartholomew, J. C., & Bradfield, C. A. (1991). Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: Comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Proceedings of the National Academy of Sciences*, 88(21), 9543–9547.
- Chen, D., Banerjee, S., Cui, Q. C., Kong, D., Sarkar, F. H., & Dou, Q. P. (2009). Activation of detoxification enzymes and antioxidant defense by diindolylmethane in prostate cancer cells. *Molecular Cancer Therapeutics*, 8(4), 1043–1052.
- Dalessandri, K. M., Firestone, G. L., Fitch, M. D., Bradlow, H. L., Bjeldanes, L. F., & Powell, C. B. (2004). Pilot study: Effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women. *Nutrition and Cancer*, 50(2), 161–167.
- Le, H. T., Schaldach, C. M., Firestone, G. L., & Bjeldanes, L. F. (2008). Plant-derived 3,3'-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. *The Journal of Biological Chemistry*, 283(16), 9896–9904.
- Reed, G. A., Peterson, K. S., Smith, H. J., Gray, J. C., Sullivan, D. K., Mayo, M. S., Crowell, J. A., Hurwitz, A., & Crowell, J. A. (2006). A phase I study of indole-3-carbinol in women: Tolerability and effects on 2- and 16 $\alpha$ -hydroxyestrone metabolism. *Cancer Epidemiology, Biomarkers & Prevention*, 15(12), 2477–2481.
- Chen, D., Banerjee, S., Cui, Q. C., Kong, D., Sarkar, F. H., & Dou, Q. P. (2019). Activation of AMP-activated protein kinase by diindolylmethane enhances prostate cancer cell death. *Molecular Cancer Therapeutics*, 18(2), 353–364.
- Helferich, W. G., Andrade, J. E., & Hoagland, M. S. (2008). Phytochemicals modulating androgen receptor signaling in prostate cancer. *Molecular Nutrition & Food Research*, 52(1), 114–127.
- Leong, H., Firestone, G. L., & Bjeldanes, L. F. (2004). Cytostatic effects of 3,3'-diindolylmethane in human prostate cancer cells are associated with G1 cell cycle arrest. *Carcinogenesis*, 25(11), 2111–2118.
- Bell, M. C., Crowley-Nowick, P., Bradlow, H. L., Sepkovic, D. W., Howell, P., & Mayeaux, E. J. (2017). Placebo-controlled trial of indole-3-carbinol in the treatment of CIN: Effects on estrogen metabolism and regression of cervical lesions. *Gynecologic Oncology*, 105(1), 1–8.
- Del Priore, G., Gudipudi, D. K., Montemarano, N., Malanowska-Stega, J., & Arslan, A. A. (2010). Oral diindolylmethane (DIM): A novel treatment for recurrent respiratory papillomatosis. *Journal of Oncology*, 2010, 1–6.
- Rahman, K. M., Aranha, O., Glazyrin, A., & Sarkar, F. H. (2013). Inhibition of NF- $\kappa$ B activation by diindolylmethane contributes to apoptosis in prostate cancer cells. *Molecular Cancer Therapeutics*, 2(10), 1043–1052.
- Choi, S., Kim, H., Lee, J., Cho, Y. Y., & Bode, A. M. (2012). 3,3'-Diindolylmethane induces apoptosis through endoplasmic reticulum stress in human colon cancer cells. *Carcinogenesis*, 33(12), 2154–2163.
- Lamas, B., Natividad, J. M., & Sokol, H. (2018). Aryl hydrocarbon receptor and intestinal immunity. *Mucosal Immunology*, 11(4), 1024–1038.
- Li, Y., Li, X., Guo, B., & Zhang, Y. (2018). Epigenetic modulation of tumor suppressor genes by 3,3'-diindolylmethane in prostate cancer. *Molecular Carcinogenesis*, 57(7), 827–839.
- Li, Y., Li, X., Guo, B., & Sarkar, F. H. (2005). Regulation of gene expression by 3,3'-diindolylmethane through histone acetylation in breast cancer cells. *The Journal of Nutrition*, 135(6), 1204–1209.
- Liang, J., Liu, H., Li, F., Luo, J., & Yang, Y. (2019). Effects of diindolylmethane on gut microbiota composition and function in mice fed a high-fat diet. *Frontiers in Nutrition*, 6, 156.
- Majumdar, A. P. N., Banerjee, S., & Sarkar, F. H. (2011). Indole-3-carbinol and diindolylmethane in colorectal cancer prevention. *Molecular Nutrition & Food Research*, 55(7), 1015–1028.
- Bradfield, C. A., & Bjeldanes, L. F. (1987). Indole-3-carbinol from cruciferous vegetables: anticarcinogen and modulator of xenobiotic metabolism. *J Nutr*, 117(11), 2002–2009.
- Plottel, C. S., & Blaser, M. J. (2011). The microbiome and the estrobolome: How the gut microbiome might influence estrogen metabolism and breast cancer risk. *Endocrinology*, 152(12), 4605–4611.

# REFERENCES

27. Traka, M. H., & Mithen, R. F. (2009). Plant science and human nutrition: Challenges in assessing health-promoting properties of phytochemicals. *Nature Reviews Genetics*, 10(6), 373–384.
28. Zhang, Y., Li, Y., & Sarkar, F. H. (2013). Indole-3-carbinol and 3,3'-diindolylmethane in breast cancer chemoprevention: Mechanistic insights and translational perspectives. *Nutrients*, 5(7), 2571–2594.
29. Anderton, M. J., Manson, M. M., Verschoyle, R. D., Gescher, A., Steward, W. P., & Williams, M. L. (2004). Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. *Clinical Cancer Research*, 10(15), 5233–5241.
30. Anderton, M. J., Jukes, R., Rannard, S. P., & Steward, W. P. (2003). Development of a solubilized formulation of 3,3'-diindolylmethane (DIM): Pharmacokinetics in rats and humans. *Drug Metabolism and Disposition*, 31(8), 841–847.
31. Reed, G. A., Peterson, K. S., Smith, H. J., Gray, J. C., Sullivan, D. K., Mayo, M. S., Crowell, J. A., & Hurwitz, A. (2006). A phase I study of indole-3-carbinol in women: Tolerability and effects. *Cancer Epidemiology, Biomarkers & Prevention*, 15(12), 2477–2481.

## PROGRAM SPECIFIC REFERENCES:

**References to pharmaceutical development programs and clinical investigations are provided solely for historical and scientific context. BIO-DiMaX® is not intended for use in the diagnosis, treatment, mitigation, or prevention of any disease.**

### CEZAROX® — Respiratory & Immune Program

Direct Cezarox® Clinical & Development Documents

1. Cezarox® Phase II Clinical Study Report. Prospective evaluation of a solubilized DIM formulation in 84 patients with acute viral respiratory infections (coronavirus, influenza A/B, parainfluenza, adenovirus, RSV). (Cezarox COVID.pdf)
2. Cezarox® Drug Development Dossier. Formulation design, dosing rationale, and clinical positioning of solubilized DIM for respiratory and immune applications. (Cezarox Drug Development.pdf)
3. Clinical Trial Register (ChiCTR) Entry for Cezarox®. Trial registration, protocol overview, and clinical endpoints for DIM-based therapy in acute respiratory infections. (Chinese Clinical Trial Register – WHO ICTRP platform.pdf)
4. DIM-based host-directed therapy in viral pneumonia models (influenza and SARS-CoV-2), including Cezarox Epi / DIM Epi formulations. (VIRAL PNEUMONIA SEVA & VADIM 2025.pdf)

### INFEMIN® — Prostate & Cellular Regulation Program

Direct Infemin® Clinical & Safety Studies

1. Paltsev MA, et al. A randomized, double-blind, placebo-controlled Phase IIa trial of Infemin® (solubilized 3,3'-diindolylmethane) in high-grade prostatic intraepithelial neoplasia. *EPMA J.* 2016;7:5. (INFEMIN DIM-reverse prostatic intraepithelial neoplasia.pdf)
2. Safety and Tolerability of DIM-Based Therapy in PIN. Evaluation of personalized solubilized DIM therapy addressing safety, tolerability, and compliance in high-grade PIN. (Safety and tolerability of DIM-based therapy designed as personalized approach to reverse PIN.pdf)
3. Infemin® Clinical Context & Cancer Meta-Analysis. Review and synthesis of DIM-based interventions in oncology contexts, including Infemin® clinical findings. (INFEMIN DIM & DIM Meta-analysis in Cancer.pdf)

### CERVIKON® — Women's Cellular Wellness (CIN I-II) Program

Direct Cervikon® Clinical & Formulation Studies

1. Sukhikh GT, Ashrafyan LA, Kiselev VI, et al. Efficacy and safety of a diindolylmethane-based intravaginal formulation in patients with cervical intraepithelial neoplasia grades 1–2. *Akkad Obstet Gynecol.* 2018;9:91–98. (Cervicon – Cervical Neoplasia.pdf)
2. Ashrafian L, Sukhikh G, Kiselev V, et al. Double-blind randomized placebo-controlled multicenter Phase IIa trial of DIM-based therapy in CIN I-II. *EPMA J.* 2015;6:25. (Vadim Cervikon Study.pdf)
3. Cervikon® DIM Suppository Clinical Evaluation. Intravaginal DIM delivery for cervical intraepithelial neoplasia: formulation, dosing, safety, and compliance. (CERVICON DIM Suppository – Cervical Neoplasia.pdf)
4. Implications of Cervikon® for Cervical Cancer Prevention. Clinical interpretation and extended discussion of Cervikon® outcomes. (Cervicon – implications for cervical cancer prevention.pdf)

## ABOUT 4POTENTIA

---

4Potentia is an innovative natural products and ingredient supplier dedicated to advancing human performance and well-being. We partner with formulators, product developers, and brand innovators in the dietary supplement, functional food, and nutraceutical industries to bring next-generation ingredients to market.

Our mission is simple yet powerful: to unlock human potential through science-backed, high-performance ingredients. By combining rigorous research, advanced formulation expertise, and a passion for innovation, we help our partners create products that truly deliver results—enhancing energy, focus, recovery, and longevity.

From discovery to commercialization, 4Potentia is redefining what's possible in natural performance nutrition. Together, we're fueling a new era of human potential.



(888) 275-3992  
INFO@4POTENTIA.COM  
4POTENTIA.COM

1255 N. TUSTIN AVE,  
ANAHEIM, CA 92807

## ADDENDUM A

### DIM MECHANISMS OVERVIEW

Mechanistic Category	Description (DSHEA-Compliant)	Physiological Context
<b>Estrogen Metabolism Support</b>	DIM modulates pathways involved in estrogen hydroxylation and metabolite balance.	General endocrine and metabolic homeostasis.
<b>Androgen-Related Pathways</b>	DIM interacts with signaling pathways associated with androgen balance.	Supports healthy estrogen-androgen ratios in men and women.
<b>Cellular Signaling Modulation</b>	Influences pathways related to cellular regulatory responses, including stress-adaptation mechanisms.	Cellular equilibrium and adaptive response.
<b>Detoxification-Associated Enzyme Activity</b>	DIM interacts with enzyme systems involved in xenobiotic metabolism.	Supports natural detoxification processes.
<b>Oxidative Balance &amp; Redox Support</b>	DIM participates in pathways associated with oxidative stress responses.	Supports natural detoxification processes.
<b>Immune &amp; Inflammatory</b>	DIM participates in pathways associated with oxidative stress responses.	Cellular protection and homeostasis.
<b>Immune &amp; Inflammatory Modulation</b>	Affects cytokine and immune-associated signaling pathways.	Supports balanced immune and inflammatory responses.

## ADDENDUM B

### BIOAVAILABILITY COMPARISON CHART

Criteria	Conventional Crystalline DIM	Pharmaceutical Solubilized DIM (Infemin <sup>®</sup> , Cezarox <sup>®</sup> , Cervikon <sup>®</sup> )	BIO-DiMaX <sup>®</sup> Nutraceutical Translation
<b>Solubility</b>	Very low, hydrophobic	High, formulation dependent	High dispersion engineered from pharma principles
<b>Absorption Consistency</b>	Variable between individuals	Predictable across dose ranges	Designed for more consistent outcomes
<b>Typical Functional Dose</b>	Often 200–300 mg+	Low-dose exposure achievable	Typically 25–50 mg use level.
<b>Tolerability</b>	GI discomfort at higher doses	Improved tolerability due to lower dose requirements	Designed for user-friendly tolerability
<b>Exposure Efficiency</b>	Low due to solubility limits	High, formulation-driven	Improved absorption efficiency relative to crystalline DIM
<b>Real-World User Experience</b>	Inconsistent	More reliable due to delivery technology	Intended to offer improved predictability